Search for: All records

There is a significant interest in testing quantum entanglement and Bell inequality violation in high-energy experiments. Since the analyses in high-energy experiments are performed with events statistically averaged over phase space, the states used to determine observables depend on the choice of coordinates through an event-dependent basis and are thus not genuine quantum states, but rather “fictitious states.” We find that the basis which diagonalizes the spin-spin correlations is optimal for constructing fictitious states to test the violation of Bell’s inequality. This result is applied directly to the bipartite qubit system of a top and antitop produced at a hadron collider. We show that the beam axis is the optimal basis choice near the $t\overline{t}$threshold production for measuring Bell inequality violation, while at high transverse momentum the basis that aligns along the momentum direction of the top is optimal. Published by the American Physical Society2024 

Particle collisions at the energy frontier can probe the nature of invisible dark matter via production in association with recoiling visible objects. We propose a new potential production mode, in which dark matter is produced by the decay of a heavy dark Higgs boson radiated from a heavyW′ boson. In such a model, motivated by left-right symmetric theories, dark matter would not be pair produced in association with other recoiling objects due to its lack of direct coupling to quarks or gluons. We study the hadronic decay mode viaW′ →tband estimate the LHC exclusion sensitivity at 95% confidence level to be 10²− 10⁵fb forW′ boson masses between 250 and 1750 GeV. 

Abstract Some of the most astonishing and prominent properties of Quantum Mechanics, such as entanglement and Bell nonlocality, have only been studied extensively in dedicated low-energy laboratory setups. The feasibility of these studies in the high-energy regime explored by particle colliders was only recently shown and has gathered the attention of the scientific community. For the range of particles and fundamental interactions involved, particle colliders provide a novel environment where quantum information theory can be probed, with energies exceeding by about 12 orders of magnitude those employed in dedicated laboratory setups. Furthermore, collider detectors have inherent advantages in performing certain quantum information measurements and allow for the reconstruction of the state of the system under consideration via quantum state tomography. Here, we elaborate on the potential, challenges, and goals of this innovative and rapidly evolving line of research and discuss its expected impact on both quantum information theory and high-energy physics. 

A rational therapeutic strategy is urgently needed for combating SARS-CoV-2 infection. Viral infection initiates when the SARS-CoV-2 receptor-binding domain (RBD) binds to the ACE2 receptor, and thus, inhibiting RBD is a promising therapeutic for blocking viral entry. In this study, the structure of lead antiviral candidate binder (LCB1), which has three alpha-helices (H1, H2, and H3), is used as a template to design and simulate several miniprotein RBD inhibitors. LCB1 undergoes two modifications: structural modification by truncation of the H3 to reduce its size, followed by single and double amino acid substitutions to enhance its binding with RBD. We use molecular dynamics (MD) simulations supported by ab initio density functional theory (DFT) calculations. Complete binding profiles of all miniproteins with RBD have been determined. The MD investigations reveal that the H3 truncation results in a small inhibitor with a −1.5 kcal/mol tighter binding to RBD than original LCB1, while the best miniprotein with higher binding affinity involves D17R or E11V + D17R mutation. DFT calculations provide atomic-scale details on the role of hydrogen bonding and partial charge distribution in stabilizing the minibinder:RBD complex. This study provides insights into general principles for designing potential therapeutics for SARS-CoV-2.